It is worth noting that Alzheimer’s disease (AD) patients were reported to have significantly less macular pigments (comprising lutein, zeaxanthin and meso-zeaxanthin) and lower serum concentrations of lutein and zeaxanthin compared to control subjects74 and that AChE inhibitors are the standard therapy for AD75. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.